← OPKO HEALTH, INC.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $1.2b | $1.1b | $990.3m | $901.9m | $1.4b | $1.8b | $1.0b | $863.5m | $713.1m | $606.9m | |
| Cost of Revenue | $564.1m | $61.2m | $803.1m | $832.7m | $1.0b | $1.3b | $857.8m | $720.0m | $494.6m | $400.9m | |
| Gross Profit (derived) | $657.6m | $1.0b | $187.1m | $69.3m | $413.3m | $487.6m | $146.4m | $143.5m | $218.5m | $205.9m | |
| Operating Expenses | $1.3b | $1.3b | $1.2b | $1.2b | $1.4b | $1.8b | $1.2b | $1.0b | — | — | |
| Operating Income (Loss) | ($73.3m) | ($280.1m) | ($171.2m) | ($274.1m) | $57.7m | $18.8m | ($226.3m) | ($157.0m) | ($152.1m) | ($117.4m) | |
| Additional Financial Items | |||||||||||
| Amortization of Intangible Assets | $64.4m | $84.7m | $67.9m | $64.8m | $56.4m | $50.3m | $87.8m | $86.0m | $82.6m | $77.9m | |
| Equity Securities, FV-NI, Realized Gain (Loss) | — | — | $2.8m | ($7.4m) | $10.3m | $3.0m | $0 | $0 | ($54.0m) | ($4.3m) | |
| Foreign Currency Transaction Gain (Loss), before Tax | $800k | $1.4m | $1.9m | $400k | $1.6m | ($1.4m) | ($1.8m) | $1.2m | ($3.8m) | ($2.0m) | |
| Gain (Loss) on Investments | ($7.7m) | ($14.5m) | ($14.5m) | ($2.9m) | ($480k) | ($629k) | ($383k) | ($107k) | ($18k) | ($29k) | |
| Goodwill, Impairment Loss | — | — | $11.7m | $26.2m | $0 | $0 | — | — | — | $0 | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | ($92.2m) | ($247.9m) | ($132.1m) | ($236.5m) | $81.7m | ($3.0m) | ($389.4m) | ($198.4m) | $45.8m | ($188.5b) | |
| Income (Loss) from Equity Method Investments | ($7.7m) | ($14.5m) | ($14.5m) | ($2.9m) | ($480k) | ($629k) | ($383k) | ($107k) | ($18k) | ($29k) | |
| Gain (Loss) on Derivative Instruments, Net, Pretax | $2.8m | $52k | $3.0m | $174k | $50k | $846k | $649k | ($781k) | ($26.2m) | ($429k) | |
| Net Income (Loss) Attributable to Parent | ($25.1m) | ($308.9m) | ($153.0m) | ($314.9m) | $30.6m | ($30.1m) | ($328.4m) | ($188.9m) | ($53.2m) | ($225.7m) | |
| Net Income (Loss) Available to Common Stockholders, Basic | ($25.1m) | ($308.9m) | — | — | — | — | — | — | — | — | |
| Net Income (Loss) Attributable to Noncontrolling Interest | $0 | $0 | — | — | — | — | — | — | — | — | |
| Earnings Per Share, Basic | ($0.05) | ($0.55) | ($0.27) | ($0.53) | $0.05 | ($0.05) | ($0.46) | ($0.25) | ($0.08) | ($0.30) | |
| Earnings Per Share, Diluted | ($0.10) | ($0.55) | ($0.27) | ($0.53) | $0.05 | ($0.05) | ($0.46) | ($0.25) | ($0.08) | ($0.30) | |
| Weighted Average Number of Shares Outstanding, Basic | 550.8m | 559.2m | 563.1m | 595.5m | 640.7m | 648.1m | 719.1m | 751.8m | 694.0m | 751.1m | |
| Weighted Average Number of Shares Outstanding, Diluted | 555.6m | 559.2m | 563.1m | 595.5m | 640.7m | 648.1m | 719.1m | 751.8m | 694.0m | 751.1m | |
| Research and Development Expense | $111.2m | $125.2m | $125.6m | $117.9m | $75.3m | $76.8m | $73.9m | $89.6m | $105.2m | $124.0m | |
| Selling, General and Administrative Expense | $490.9m | $521.0m | $358.3m | $343.3m | $355.6m | $468.9m | $372.7m | $300.6m | $304.2m | $223.0m | |
| Other Nonoperating Income (Expense) | $3.9m | $10.5m | $1.5m | ($11.3m) | $12.7m | ($14.8m) | ($155.8m) | ($17.0m) | $206.9m | ($29.9m) | |
| Interest Expense (non-operating) | — | — | — | — | — | — | — | — | $47.5m | $108.5m | |
| Costs and Expenses | — | — | — | — | — | — | — | — | $865.2m | $724.3m | |
| Current Income Tax Expense (Benefit) | $5.4m | $2.8m | ($3.6m) | $2.7m | $2.0m | $5.3m | $10.9m | $4.3m | $28.1m | ($714k) | |
| Interest Expense | $7.4m | $6.6m | $11.9m | $21.5m | $21.9m | $18.9m | $12.1m | $13.5m | $47.5m | $0 | |
| Income Tax Expense (Benefit) | ($56.1m) | $18.9m | ($38.7m) | $7.1m | $17.6m | $15.5m | ($63.5m) | $4.4m | $42.8m | ($15.7m) |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.